You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
433 Talimogene laherparepvec (T-VEC) in combination with ipilimumab (IPI) versus IPI alone for advanced melanoma: 4-year interim analysis of a randomized, open-label, phase 2 trial

 

Online download statistics by month:

Online download statistics by month: November 2020 to November 2025

AbstractFullPdf
Nov 2020178015
Dec 20202003
Jan 20212204
Feb 20212708
Mar 20217209
Apr 20212803
May 2021806
Jun 20210010
Jul 20210019
Aug 20210016
Sep 2021008
Oct 202152029
Nov 202154019
Dec 20213804
Jan 20223402
Feb 20223808
Mar 202298016
Apr 2022128015
May 20228606
Jun 2022100012
Jul 20226405
Aug 2022110014
Sep 20226608
Oct 20224202
Nov 202210809
Dec 20223803
Jan 20236806
Feb 2023110013
Mar 20236606
Apr 20238405
May 202310504
Jun 20234405
Jul 202380012
Aug 20232602
Sep 20231403
Oct 20234006
Nov 20234803
Dec 20236402
Jan 20246600
Feb 20242200
Mar 20243200
Apr 20242401
May 20247601
Jun 20244303
Jul 20248403
Aug 20242201
Sep 20244803
Oct 202442011
Nov 20243204
Dec 20242802
Jan 20253207
Feb 2025606
Mar 2025005
Apr 20250012
May 2025005
Jun 2025103
Nov 2025002
Total27180389